SEEL (Seelos Therapeutics Inc.) Net earnings per one share for the last twelve months

Seelos Therapeutics, Inc (SEEL) - corporate logo

The absence of cash flows and failed tests render the outlook negative, which is confirmed by the Seelos Therapeutics (SEEL) net income per share YoY ttm growth rate chart. The 43.60 mark reflects fresh data amid a liquidity shortage. Risks are exacerbated by capital burn and potential failures in depression therapy, while geopolitics hinder international research, generating losses when tests are halted.

seelostherapeutics.com (SEEL) Net earnings per share (EPS TTM): for the period 02/11/2024 - 02/20/2024

SEEL (seelostherapeutics.com): analytical breakdowns and indicator data

- market price and analyst price targets:
- business market valuation indicators:
Fundamental company valuation:SEEL, Seelos Therapeutics, Inc.
Core merchandise of Seelos Therapeutics

To assess the scale of Seelos Therapeutics (SEEL), use the trailing twelve-month (TTM) year-over-year EPS chart. This indicator reflects the dynamics of net income per share relative to the same period last year. The calculation measures business capitalization efficiency and real income growth rates. For this developer of nasal CNS therapies, this metric signals a transition from R&D expenditures to monetization. Steady growth in this metric confirms the company's investment attractiveness.